– USA. FL – NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced the appointment of Felicia Williams to its Board as an independent director effective November 1, 2024.
“We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics,” said Board chair, Lynn Tetrault. “We look forward to working together to support the company and improve patient care.”
Felicia Williams has joined the Audit and Finance and Nominating and Corporate Governance Committees.
About Felicia Williams
Felicia Williams has had a multi-dimensional business career across the spectrum of finance, including Treasury, enterprise risk management, accounting, and audit. Felicia has more than 35 years of experience leading multinational corporations such as Macy’s, Inc., The Coca-Cola Company, and Bristol Myers-Squibb. She is also a member of the Board of Directors of Paycom and Anywhere Real Estate. Felicia is the former interim CFO of Macy’s Inc. and a Fellow for CEO Action for Racial Equality.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP-accredited and CLIA-certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and Carlsbad, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP-accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
For more: https://neogenomics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.